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Abstract Prostanoids are a group of potent bioactive lipids
produced by oxygenation of arachidonate or one of several
related polyunsaturated fatty acids. Cellular prostaglandin
biosynthesis is tightly regulated, with a large part of the control
exerted at the level of cyclooxygenase catalysis by prostaglandin
H synthase (PGHS). The two known isoforms of PGHS have
been assigned distinct pathophysiological functions, and their
cyclooxygenase activities are subject to differential cellular
control. This review considers the contributions to cellular
catalytic control of the two PGHS isoforms by intracellular
compartmentation, accessory proteins, arachidonate levels, and
availability of hydroperoxide activator.
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Eicosanoids comprise a diverse group of oxygenated metab-
olites of polyunsaturated fatty acids (prototypically arachi-
donic acid), and include prostanoids (the various prostaglan-
dins, prostacyclin, and thromboxane), the leukotrienes, and
various epoxy, hydroperoxy, and hydroxy fatty acids [1]. Bio-
synthesis of each eicosanoid begins with oxygenation of the
fatty acid. For the prostaglandins, thromboxane, and prosta-
cyclin, this key committed step is catalyzed by the cyclooxy-
genase activity of prostaglandin H synthase (PGHS; also
known as prostaglandin endoperoxide synthase), which con-
verts arachidonic acid to prostaglandin (PG) G2. PGHS also
has an e⁄cient heme-dependent peroxidase activity, which
reduces the C15 hydroperoxide on PGG2 to an alcohol, form-
ing PGH2.
Much early characterization of PGHS was done with an
enzyme, now called PGHS-1, isolated from ovine and bovine
seminal vesicles. A second isoform of PGHS, termed PGHS-2,
was discovered in 1991 (reviewed in [2]). Both isoforms have
cyclooxygenase and peroxidase activity and their basic reac-
tion mechanisms are probably similar [3]. However, the iso-
forms have distinct genes and distinct regulation of gene ex-
pression. PGHS-1 message and protein are found in most cells
at rather stable levels. As a result, PGHS-1 is considered a
housekeeping enzyme, supplying prostanoids crucial for basal
functions (e.g. hemostasis, gastric cytoprotection). On the oth-
er hand, PGHS-2 message and protein are at very low or
undetectable levels in most quiescent cells, but are strongly
and rapidly induced in some cells responding to cytokines
and mitogens. PGHS-2 is thus referred to as the ‘inducible’
PGHS isoform, and has been assigned important roles in in-
£ammation and proliferation [2].
PGHS-2 has emerged as an important pharmacological tar-
get because selective inhibitors of the PGHS-2 cyclooxygenase
are expected to be e¡ective anti-in£ammatory agents while, by
sparing PGHS-1 cyclooxygenase activity, avoiding the side
e¡ects common with the non-speci¢c anti-cyclooxygenase
agents currently in wide use, such as aspirin, naproxen, and
indomethacin [2,3]. Interestingly, PGHS-2 appears elevated in
many (but not all) human colon tumors, and use of anti-cy-
clooxygenase agents is associated with a dramatically reduced
risk of colon cancer, although the identity of the pharmaco-
logical target remains controversial [4].
Prostanoids derived from PGH2 are potent bioactive lipids,
and so PGH2 biosynthesis is tightly controlled. Studies in cells
possessing both PGHS isoforms have demonstrated important
regulation of prostaglandin synthesis occurs at the level of
catalytic activity, with strikingly di¡erent control of PGHS-1
and PGHS-2 catalysis. The best studied examples are macro-
phages and ¢broblasts, which have constitutive levels of
PGHS-1 [2]. In these cells, mitogen stimulation leads to in-
duction of PGHS-2, considerable arachidonate release, and
conversion of a fraction of the arachidonate to prostaglan-
dins. Antisense oligonucleotide against PGHS-2 sequences
blocks PGHS-2 induction and the burst of prostaglandin syn-
thesis, but it does not impede arachidonate release nor does it
change the PGHS-1 protein level [5]. Selective PGHS-2 cyclo-
oxygenase inhibitors have e¡ects similar to PGHS-2 antisense
oligonucleotide in mitogen-treated cells [2]. It is thus clear that
the burst of prostaglandin synthesis triggered by cytokines or
mitogens originates from PGHS-2 cyclooxygenase catalysis,
with the large amount of PGHS-1 in the same cells remaining
latent even though considerable unesteri¢ed arachidonate is
released.
Induction of PGHS-2 makes only a small impact on the
overall prostaglandin biosynthetic capacity in macrophages
and ¢broblasts, and prostaglandin biosynthesis from endoge-
nous substrate is only a small fraction of overall prostaglan-
din synthetic capacity regardless of whether one or both iso-
forms are present [5^7]. Induction of PGHS-2 thus is clearly
not required to overcome insu⁄cient catalytic capacity, but
rather has the e¡ect of supplementing a latent enzyme, PGHS-
1, with a catalytically active enzyme, PGHS-2. This raises
interesting questions of what keeps PGHS-1 latent while
PGHS-2 is active, and what bene¢t induction of the second
isoform might have for the cell. Several explanations for this
di¡erential catalytic regulation of the isoforms can be consid-
ered (see scheme in Fig. 1).
(a) Access of the isoforms to distinct arachidonate pools via
di¡erential compartmentation or coupling with distinct phos-
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pholipases or accessory proteins (A and B in Fig. 1). This
explanation was prompted by the observation that PGHS-2
formed prostaglandins from endogenous arachidonate, where-
as PGHS-1 catalysis required exogenous arachidonate [5]. Im-
muno£uorescence studies supported a di¡erential compart-
mentation of the isoforms, with more PGHS-2 in the
nuclear envelope than in the ER membrane, and PGHS-1
equally distributed between the two locations [8]. Very recent
immunoelectron microscopy studies, however, have found
roughly equal amounts of both PGHS-1 and -2 in the inner
and outer nuclear membranes in several cell types [9]. Because
only the outer nuclear membrane is contiguous with the ER
membrane, this indicates that the two isoforms are similarly
distributed (at least on a macro scale) in intracellular mem-
branes. Several prostaglandin biosynthetic enzymes and sub-
strate lipid precursors also are found in non-membranous,
cytosolic lipid bodies which accumulate in cells associated
with in£ammation, although the amounts of each PGHS iso-
form present in these organelles have not been determined
[10].
Data suggesting coupling of particular phospholipases with
one or the other PGHS isoform have been reported, but a
consistent pattern of coupling partners has yet to emerge [11^
13]. Arachidonate binding accessory proteins analogous to the
5-lipoxygenase activating protein [14] could conceivably deliv-
er fatty acid speci¢cally to one of the isoforms, but candidate
proteins have not been identi¢ed, and neither cyclooxygenase
activity is impaired by puri¢cation to remove other cellular
components. Channelling of arachidonate to a particular
PGHS isoform seems di⁄cult to reconcile with the observa-
tion that arachidonate release is in large excess over prosta-
glandin synthesis, with much of the excess escaping from the
cell [5]. In addition, extracellular fatty acid scavengers, such as
serum albumin and cyclodextrin, inhibit prostaglandin synthe-
sis from endogenous substrate in some cells [15], indicating
that the intracellular arachidonate available for prostaglandin
synthesis equilibrates with the extracellular fatty acid pool.
(b) Di¡erences in the dependence of the isoforms’ cyclooxy-
genase activities on arachidonate concentration. Puri¢ed
PGHS-1 was found to have a sigmoidal dependence on arach-
idonate concentration, whereas PGHS-2 displayed simple sat-
urable behavior [16]. This was interpreted as evidence for
allosteric activation of PGHS-1 cyclooxygenase by the fatty
acid. Sigmoidal kinetics also have been observed for PGHS-1
activity in intact cells [17]. In principle, the di¡erence between
the isoforms in response to substrate level could give PGHS-2
a 2^4-fold catalytic advantage over PGHS-1 at the low arach-
idonate levels expected within cells [16]. The structural basis
for cooperative behavior in PGHS-1 is not well de¢ned,
although a sigmoidal response to arachidonate was induced
in PGHS-2 by mutation of Tyr341 to phenylalanine [18].
(c) Di¡erences in hydroperoxide activator requirement (C in
Fig. 1). The cyclooxygenase activity in both PGHS-1 and -2 is
inherently latent. Cyclooxygenase activation requires reaction
of the PGHS peroxidase with hydroperoxide, which in one
proposed mechanism [19,20] entails generation of peroxidase
compound I and its subsequent conversion to a tyrosyl radical
species (steps 1 and 4 in Fig. 2). The tyrosyl radical is prob-
ably on Tyr385 in PGHS-1 and on the corresponding residue,
Tyr371, in PGHS-2 [21^25]. Tyr385=371 lies at the end of the
cyclooxygenase channel, oriented toward the fatty acid bind-
ing site [26^28], a spatial arrangement consistent with the
mechanism in Fig. 2.
With adequate arachidonic acid and oxygen present, acti-
vation of a single PGHS molecule produces about 103 mole-
cules of PGG2, itself a hydroperoxide [29]. Di¡usion of this
PGG2 to latent PGHS nearby can progressively activate the
bulk PGHS in a chain reaction with powerful feedback char-
acteristics (Fig. 2). The requirement for activation provides a
means for cellular control of cyclooxygenase catalysis because
the bulk enzyme can be kept latent if su⁄cient PGG2 is in-
tercepted by peroxide scavengers such as glutathione peroxi-
dase, a common cytosolic peroxidase [29]. Cyclooxygenase
activation in PGHS-2 has a peroxide requirement of about
2 nM, an order of magnitude lower than that in PGHS-1,
and the two isoforms respond independently to the hydroper-
oxide level even when both are in the same compartment
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Fig. 1. Cartoon showing potential routes for di¡erential cellular
control of cyclooxygenase catalysis by PGHS-1 and -2. GSH Px,
glutathione peroxidase; ROOH, hydroperoxide.
Fig. 2. Hypothetical tyrosyl radical reaction mechanism for individ-
ual PGHS molecules (based on [19]), and feedback activation
scheme for bulk PGHS cyclooxygenase by the cyclooxygenase prod-
uct, PGG2. Enzyme symbols indicate the overall oxidation state of
the peroxidase heme (III, V(O), or IV(O)), and whether Tyr385
(Tyr371 in PGHS-2) is in the ground state (Y) or carries a tyrosyl
radical (Y*). ROOH and ROH, hydroperoxide and the correspond-
ing alcohol; Cmpd I and Cmpd II, peroxidase compounds I and II;
e3, reducing equivalent; AA, arachidonic acid.
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[30,31]. As a result, a considerable fraction of PGHS-2 cyclo-
oxygenase can be in the catalytically active state at hydroper-
oxide levels where the large majority of PGHS-1 activity is
latent. Release of arachidonate by cellular phospholipases
under such circumstances would permit prostaglandin synthe-
sis via PGHS-2 but not by PGHS-1.
Di¡erential control of catalysis in PGHS-1 and PGHS-2 via
cellular peroxide level has several appealing features which
accord with experimental observations. Regulation by perox-
ide does not require physical sequestration of the proteins,
peroxide activator, or arachidonate. This ¢ts with the ease
with which fatty acids cross lipid membranes [32] and the
apparent equilibration of intracellular and extracellular arach-
idonate pools [15]. The ratio of peroxide scavenging capacity
(measured as glutathione peroxidase activity) to cyclooxyge-
nase capacity in tissues ranges from 10 in cells with active
prostaglandin synthesis to near 2000 in tissue with little pros-
taglandin synthesis [29]. This range of glutathione peroxidase/
cyclooxygenase capacity ratio in tissues spans the ratios of 70
observed for complete suppression of puri¢ed PGHS- 1 and
700 for complete suppression of puri¢ed PGHS-2 [31], sug-
gesting that the amounts of cellular peroxidases are su⁄cient
to poise intracellular peroxides at levels consistent with cata-
lytic control. Control of cyclooxygenase catalysis via peroxide
level also provides an attractive rationale for the observed
induction of PGHS-2 in cells already containing PGHS-1.
Induction of the more readily activated PGHS-2 would allow
a cell to dramatically increase the rate of prostaglandin syn-
thesis without increasing the cellular peroxide tone, thereby
avoiding the increased risk of damage to DNA, protein, and
lipid which accompanies elevated peroxide levels.
A hydroperoxide-based cyclooxygenase regulatory regime
could conceivably be linked to the nitric oxide (NO) pathway
because peroxynitrite, a NO metabolite, is a cyclooxygenase
activator [33]. This indirect cyclooxygenase activation via per-
oxynitrite requires appreciable levels of superoxide [33], which
is not produced during catalysis by puri¢ed PGHS unless
particular cosubstrates, such as NADH or NADPH, are
added [34]. Direct activation of PGHS-1 and -2 cyclooxyge-
nase activity by nitric oxide or NO donors has been reported
(e.g. [35,36]). However, such activation has proven di⁄cult to
reproduce, even with enzyme from the same sources (e.g.
[37,38]). In addition, a biochemical basis for direct cyclooxy-
genase activation by NO has yet to be demonstrated convinc-
ingly. NO has only very weak a⁄nity for the ferric heme in
PGHS-1, with a Kd value of 0.9 mM [37]. NO does bind
tightly to ferrous PGHS-1 heme [37], but the ferrous state is
rapidly oxidized in air and is not observed during catalysis
[19]. These properties make it very unlikely that NO is a
signi¢cant PGHS heme ligand at the low micromolar levels
expected in vivo. Furthermore, PGHS heme ligands generally
inhibit, rather than activate, cyclooxygenase activity [39]. Ni-
trosothiol formation on PGHS cysteine residues has been pro-
posed as a mechanism for cyclooxygenase activation by NO
[36], but the published data yield an implausibly high stoichi-
ometry of PGHS nitrosothiol formed/NO added (s 4), indi-
cating that the issue needs to be re-examined.
The actions of each of the three individual factors described
above in di¡erential catalytic control of the PGHS isoforms in
vivo are being actively examined. Some of the recent evidence
suggests a new hypothesis needs to be considered: that fatty
acid and hydroperoxide levels interact to play the dominant
role in regulation of cyclooxygenase catalysis. In the proto-
typical ¢broblast model, PGHS-1 cyclooxygenase activity is
released from the latent form by raising the hydroperoxide
level [[40] ; R. Kulmacz and W. Chen, unpublished observa-
tions], and PGHS-2 cyclooxygenase activity is suppressed by
decreasing cellular hydroperoxides [17]. In the same intact cell
model, PGHS-2 catalysis occurs readily with low arachidonate
levels, whereas PGHS-1 catalysis requires higher fatty acid
substrate levels [17]. However, the hydroperoxide and fatty
acid levels do not exert their in£uences independently, as
can be appreciated from the feedback activation scheme
shown in Fig. 2. Activation of latent cyclooxygenase requires
hydroperoxide (PGG2) accumulation, and formation of that
PGG2 requires arachidonate. Thus, catalysis by the cellular
cyclooxygenases could be expected to be modulated in an
interdependent fashion by both the hydroperoxide level and
the supply of arachidonate. Further investigation of the dy-
namics of this interplay between the substrates and products
of the two PGHS isoforms should help to elucidate how cel-
lular prostanoid synthesis is controlled.
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